Ozempic / Semaglutide (GI) Lawsuit Update (August 2026)

Ozempic mass tort case acquisition has emerged as one of the highest-volume plaintiff-side opportunities in the current litigation cycle, with MDL 3094 centralizing thousands of gastroparesis and bowel obstruction claims against Novo Nordisk. The claimant pool spans tens of millions of semaglutide users, and early advertising economics still favor firms that move before cost-per-lead climbs. For plaintiff firms evaluating docket exposure and intake infrastructure, the central question is no longer whether this litigation is viable, it is whether your firm is positioned to compete now.

The Litigation Landscape and What It Means for Your Timing

MDL 3094 is centralized in the Eastern District of Pennsylvania before Judge Gene Pratter. The docket crossed 10,000 active plaintiffs and is still growing rapidly. Centralization happened in late 2023, which means the litigation is relatively young by MDL standards. Discovery is ongoing, no bellwether trial dates are locked in, and settlements are not on the table yet. Bellwether trials are estimated no earlier than 2026, and realistically could push further depending on the pace of science and expert discovery.

That timeline has direct implications for how firms should think about capital deployment. Early MDLs carry more uncertainty, but they also carry lower acquisition costs and less competition for claimants. Once bellwether results come in and the science firms up, lead prices spike and every generalist firm in the country starts advertising. The firms that built their inventory in the discovery phase tend to capture the best economics.

The injury tracks are multiple, which is unusual and worth understanding. The primary track is gastroparesis (severe stomach paralysis) and intestinal obstruction. A second track involves aspiration pneumonia during surgery caused by retained stomach contents in patients who fasted pre-operatively but remained on GLP-1 drugs. Several aspiration deaths have been reported. The third track, getting significant attention in 2025 and 2026, is NAION, non-arteritic anterior ischemic optic neuropathy, which is essentially a blockage of blood flow to the optic nerve causing sudden and often irreversible vision loss. Studies estimate NAION affects roughly 1 in 10,000 GLP-1 users, but with tens of millions of prescriptions, that translates to a meaningful plaintiff population.

The legal theory across all three tracks is failure to warn. The FDA required Novo Nordisk to update gastroparesis risk labeling in 2023, which strengthens the pre-warning cases considerably. The defendants are Novo Nordisk on the semaglutide side and Eli Lilly on tirzepatide (Mounjaro). Both are deep-pocket defendants capable of funding a large settlement when the time comes.

Claimant Pool Size and Market Saturation

GLP-1 drugs have been prescribed in all 50 states with no geographic concentration. This is a nationwide tort with no meaningful regional clustering, which simplifies media buying but also means competition for claimants is coming from every direction. Prescription volumes are staggering, over 50 million GLP-1 prescriptions were written in 2023 alone, and total users in the U.S. over the litigation-relevant period number in the tens of millions.

On the gastroparesis track specifically, the qualifying population is large because the injury is documented, severe, and supported by hospitalizations, endoscopies, gastric emptying studies, and specialist treatment records. These are not soft-injury cases. On the NAION track, the estimated rate of 1 in 10,000 sounds small until you multiply it across the total exposed population, and you are looking at a potentially substantial plaintiff pool that is still largely unaware of the litigation connection.

Is the market saturated? Not yet, but it is moving. The combination of rapid docket growth and mainstream media coverage of Ozempic generally has raised awareness among injured patients. Law firm advertising on this tort ramped meaningfully through 2024 and 2025. However, compared to torts like Camp Lejeune or talcum powder at equivalent litigation stages, Ozempic advertising volume is still relatively moderate. There is room to acquire cases at reasonable economics if you move with a structured campaign rather than testing haphazardly.

Ozempic Mass Tort Case Acquisition Economics: What the Numbers Look Like

This is where firms need to get honest with themselves before committing budget. Advertising economics for Ozempic mass tort case acquisition are in a competitive but not yet punishing range. Current cost-per-lead on well-run campaigns typically falls between $150 and $350 depending on injury track, channel, and creative quality. Cost-per-signed-case, accounting for qualification rate and conversion from lead to retainer, is running in the range of $1,200 to $2,800 for gastroparesis-track cases. NAION cases are somewhat harder to generate at scale because the condition is less familiar to the public, but when generated, they tend to qualify at a strong rate.

Meta (Facebook and Instagram) remains the primary acquisition channel for this tort. The audience targeting on Meta for GLP-1 users is reasonably precise given the drug's widespread media coverage, and interest and behavioral signals can be layered to reach people who have discussed weight loss medications or who are in the relevant demographic and prescription windows. YouTube pre-roll has shown good performance for this tort at firms with video creative budgets. Programmatic display and native advertising are secondary channels that work well for retargeting and for reaching users who have already shown intent.

Creative angles that convert focus on the specific injury rather than the drug name alone. Gastroparesis creative emphasizing nausea, vomiting, hospitalization, and diagnosed stomach paralysis outperforms generic "Ozempic lawsuit" messaging. For NAION, sudden vision loss connected to Ozempic use is the hook. The key on creative is specificity. Claimants with documented injuries recognize their own situation when the creative is precise.

From a pure acquisition math standpoint, firms targeting a 4:1 to 6:1 return on case acquisition cost need to be underwriting case value in the range of $6,000 to $20,000 at current CPL levels, depending on injury severity. Aspiration death cases carry significantly higher value. Pre-trial MDL inventory built now at current pricing could look very attractive after bellwether verdicts if the science holds.

Intake and Qualification: How to Make Cases Stick

Intake on Ozempic cases requires a structured qualification protocol. The core criteria across the primary injury tracks are: confirmed GLP-1 drug use (Ozempic, Wegovy, Mounjaro, Rybelsus), a diagnosed qualifying injury (gastroparesis, intestinal obstruction, aspiration pneumonia, or NAION), medical documentation of that injury, and a timeline connecting drug use to onset. Cases without medical records confirming the diagnosis are weak and should not be signed at standard case values.

The records request process matters as much as the intake call. Firms that request gastric emptying study results, hospital discharge summaries, GI specialist notes, or ophthalmology records before final retainer execution are building a portfolio that will survive defense scrutiny. Cases signed on self-report alone create downstream risk when discovery opens and records do not support the claim.

Retainer flow benefits from digital execution. Claimants on this tort tend to be adults in their 40s through 60s who are comfortable with e-signature platforms. Fast turnaround from intake call to signed retainer, within 24 to 48 hours, meaningfully reduces case fall-off. AI-assisted intake tools are increasingly being deployed by plaintiff firms to accelerate screening and flag qualification gaps before a case reaches an attorney. For firms interested in operationalizing this, the strategies in A Lawyer's Guide to AI cover exactly this kind of intake workflow and where AI tools add the most leverage.

How MTAA Runs Ozempic Campaigns

At MTAA, we have run advertising across 100-plus mass torts and managed over $250 million in Facebook ad spend for more than 600 plaintiff firms. Ozempic is currently an active campaign we run for client firms. Our pricing model is transparent: ad spend plus a flat 15 percent fee, no hidden markups, no inflated CPLs. What that means practically is that a firm spending $50,000 in ad spend pays $7,500 in fees and gets full campaign management including creative development, targeting strategy, compliance review, and performance reporting.

For Ozempic specifically, we run separate creative tracks for gastroparesis and NAION because the audiences and injury recognition patterns differ. We test landing page messaging, screen call scripting, and lead delivery speed to optimize the full funnel from click to signed case. Firms working with us on this tort are building case inventory now, ahead of what we expect will be a meaningful CPL increase once bellwether dates are announced publicly and national advertising volume increases.

The Window Is Open, But It Will Not Stay This Wide

Mass tort advertising follows a predictable pattern. Cost and competition are lowest during discovery, before verdicts create settlement urgency and before every media buyer in the country floods the channel. Firms that evaluate Ozempic mass tort case acquisition seriously right now, with a real budget and a real intake process, are positioned at the favorable part of that curve. MDL 3094 has strong causation science, documented serious injuries, deep-pocket defendants, and a plaintiff population in the tens of millions. The science is still developing, which carries risk, but the trajectory is clear enough that waiting for certainty will cost you case economics.

Whether you are running campaigns internally or working with a media partner, the core decision is the same: do the acquisition math, build an intake process that captures qualified cases cleanly, and decide how much inventory you want to carry into what could be one of the defining pharmaceutical mass torts of this decade. Ozempic mass tort case acquisition done right, with disciplined spending and tight qualification, is one of the stronger business opportunities in the plaintiff bar right now. Firms that treat it casually will pay more for less later.